Introduction
============

Depression is a psychiatric illness that is moderately heritable (*h*^2^=40--50%)^[@bib1]^ and has a high prevalence (8.6--17.1%).^[@bib2],\ [@bib3],\ [@bib4]^ Although all earlier genome-wide association studies (GWAS) failed to identify genes underlying depression in European populations,^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ 17 common genetic variants were recently identified only after increasing the sample size to over 75 000 cases and 230 000 controls^[@bib11]^ in the GWAS. All identified variants are non-coding with modest effects on depression (odds ratio\<1.05) and together explain a small percentage of variation in depression.^[@bib11]^ Although expanding array-based GWAS further may deliver more common genetic variants associated with depression, the effects of these variants will be even smaller and will have little or no impact on the familial risk of depression.^[@bib12],\ [@bib13],\ [@bib14]^ The proportion of variance of depression risk explained by common genetic variants was estimated at 21%,^[@bib15],\ [@bib16]^ suggesting that there is influence of additional mechanisms such as rare genetic variants, which have not yet been as rigorously studied for depression as the common genetic variants. We have recently identified a rare missense variant in the *LIPG*^[@bib17]^ gene and several coding variants in *NKPD1*^[@bib18]^ gene associated with depressive symptoms. The estimated impact of these variants on depressive symptomology is large.^[@bib17],\ [@bib18]^ In addition, two relatively small studies have nominally implicated rare genetic variants in *ZNF34* and Cav2-adaptor genes in depression.^[@bib19],\ [@bib20]^ These studies corroborate the contribution of rare variants to the etiology of depression.

Next-generation sequencing (NGS) has greatly facilitated the opportunity to study rare variation in the human genome.^[@bib21]^ However, as statistical power in a genetic association study is partly determined by the frequency of the genetic variant, large sample sizes are required to have sufficient statistical power to implicate rare variants with high confidence.^[@bib22]^ As NGS is still expensive, large-scale whole-genome/exome sequencing is not yet feasible,^[@bib21]^ which impedes the discovery of rare genetic variants through GWAS-like studies. However, unlike common variants (with a few exceptions), rare variants may also be studied in small samples in family-based studies.^[@bib21]^ As both alleles from the parent are equally likely to be transmitted to the offspring, rare alleles can be enriched in families and can be localized through positional cloning.^[@bib23],\ [@bib24],\ [@bib25]^ Further, individuals from a family are likely to share the same phenotype and environmental factors^[@bib26]^ besides genetics.

Apart from family-based studies other designs including extreme-phenotype sampling^[@bib22]^ and use of population isolates have been suggested to increase the chances of the discovery of rare genetic variants^[@bib21]^ in smaller samples. Although individuals with extreme phenotypes are expected to be more homogenous and enriched for rare variants with large effects,^[@bib25]^ isolated populations, besides being characterized by reduced phenotypic and genotypic heterogeneity, are also enriched for rare alleles due to isolation and genetic drift.^[@bib27]^ For a complex and heterogeneous trait like depression, these factors can help increase the power to detect genetic variation that is rare in the general population. There is, however, a risk with such designs that the identified variants may not be relevant for the general population.^[@bib21],\ [@bib22]^

In the current study, to identify rare genetic variants associated with depression, we performed positional cloning using sparse genotyping in individuals selected for a high burden of depressive symptoms and clustered in families from an isolated population. Next, we identified the relevant mutations using NGS in informative individuals and families. We then replicated our findings in a cosmopolitan population. Finally, to understand the mechanisms through which the identified gene may be relevant for depression, we performed gene expression analysis in human and mice brain to localize the cell types in which the gene harboring the identified mutation is expressed.

Material and Methods
====================

Study populations
-----------------

The discovery population consisted of subjects from the Erasmus Rucphen Family (ERF), which is a genetically isolated community in the South-West of the Netherlands, and studied as part of the Genetic Research in Isolated Populations (GRIP) program.^[@bib28]^ ERF includes \~3000 individuals who are living descendants of 22 founder couples who each had at least six children baptized in the community church. All data were collected between 2002 and 2005. The population exhibits minimal immigration and high inbreeding, resulting in a skewed distribution of rare allele frequencies.^[@bib28]^ Depressive symptoms were evaluated using the Center for Epidemiologic Studies Depression (CES-D) and the Hospital Anxiety and Depression Scale (HADS). The HADS is a 14-item scale of which 7 relate to anxiety and 7 to depression. For depressive symptoms (HADS-D), the total score ranges from 0 to 21 with a higher score representing a higher burden of depressive symptoms. A cutoff of 11 has been validated as indicative of a current major depressive episode.^[@bib29],\ [@bib30]^

The replication cohort included subjects from the Rotterdam study (RS). RS is a prospective, population-based study from the district of Ommoord within the city of Rotterdam, designed to investigate the occurrence and determinants of diseases in the elderly.^[@bib31]^ The cohort was initially defined in 1990 among 7983 persons who underwent a home interview and extensive physical examination at baseline and follow-up examinations occurring every 3--4 years (RS-I). The cohort was further extended in 2000 (RS-II) and 2005 (RS-III), establishing a total of 14 926 participants.^[@bib31]^ RS is an outbred population, predominantly of Dutch origin. Participants from RS-I were assessed during four follow-up visits for depressive symptoms using the 20-item version of the CES-D scale. Data from the third follow-up visit was used in this study to maximize the sample size.

This study was approved by the Medical Ethical Committee of the Erasmus University Medical Center (Rotterdam, The Netherlands). All participants provided written informed consent to participate.

Genotyping
----------

### Linkage array

Genotyping was performed on 6 K Illumina Linkage IV Panels (Illumina, San Diego, CA, USA). After removing variants with a low call rate (\<98%) or diverging from Hardy--Weinberg equilibrium (*P*-value\<10^−08^), and removing individuals with a low call rate (\<96%), 5250 single-nucleotide polymorphisms were retrieved from 3018 individuals. Mendelian inconsistencies were designated as missing.

### Exome sequencing/genotyping

The exomes of 1336 individuals from the ERF study were sequenced at the Center for Biomics (Department of Cell Biology, Erasmus MC, Rotterdam, The Netherlands). Sequencing was performed at a mean depth of 74x (Agilent Technologies, Santa Clara, CA, USA, version 4 capture) on an Illumina Hiseq2000 sequencer using the TruSeq Version 3 protocol. After quality control we retrieved 543 954 high-quality single nucleotide variants (SNVs) in 1327 individuals. Individuals, whose exomes were not sequenced (*N*=1527) were genotyped on the Illumina Infinium HumanExome BeadChip, version 1.1. Calling was performed with GenomeStudio. In RS, exomes of 2628 randomly selected individuals from the RS-I population were sequenced at an average depth of 54 × (Nimblegen SeqCap EZ V2 capture) on an Illumina Hiseq2000 sequencer using the TrueSeq Version 3 protocol. The final dataset after quality control consisted of 600 806 SNVs among 2356 individuals, of which 1604 had CES-D data available. Details of sequencing and genotyping are provided in the supplement.

Statistical analyses
--------------------

### Linkage and haplotype analyses

To identify loci that might harbor large-effect-rare variation, we performed an affected-only linkage analysis using individuals from ERF scoring \>90th percentile (score \>12) of the HADS-D distribution (*N*=218; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). These 218 affected individuals were related to each other in \>10 generations in a large multiplex pedigree consisting of 6562 individuals. PEDCUT software^[@bib32]^ was used to cluster the 218 affected individuals into 48 non-overlapping sub-pedigrees to facilitate linkage analysis. Multipoint non-parametric and parametric linkage analyses were performed using MERLIN 1.1.2.^[@bib33]^ Parametric linkage analysis was performed assuming incomplete penetrance and no phenocopies under dominant (0, 0.5, 0.5) and recessive models (0, 0, 0.5).^[@bib34]^ Subsequently, to identify sub-families contributing to each linkage peak (henceforth referred to as contributing families), a 'per family' linkage analysis was performed for each locus of interest. To identify individuals contributing to the linkage scores of each locus, we constructed haplotypes using SIMWALK2.^[@bib35]^ Linked regions for which we could ascertain a distinct segregating haplotype were followed up with fine mapping.

### Identification of variants under the linkage peaks

Exome sequence data was used to identify variants that could explain the observed linkage peaks in the ERF discovery cohort. For each linkage region, we considered only rare (minor allele frequency (MAF)\<0.05) and coding (missense, stop-coding) SNVs located within the corresponding haplotypes. To identify variants that could explain the corresponding linkage signal, we searched for variants shared by at least two affected haplotype carriers. Candidate variants were subjected to quantitative trait association analysis with depressive symptoms adjusted for age and gender using the 'fastAssoc' option in MERLIN 1.1.2. In RS, the replication cohort, quantitative trait association analysis of depressive symptoms (CES-D-scale) adjusted for age and gender was performed using seqMeta (v1.4) (<http://cran.r-project.org/web/packages/seqMeta/index.html>).

Human brain material
--------------------

All procedures with human tissue were performed with the approval of the Medical Ethical Committee of the Erasmus MC Rotterdam, including written consent of all subjects for brain donation in accordance with Dutch license procedures and the Declaration of Helsinki. Fresh-frozen postmortem tissue blocks containing the middle frontal gyrus (BA9) from three donors were obtained from the Erasmus MC Department of Pathology ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Donors were confirmed to have no past medical history of any known psychiatric or neurologic illness, with additional confirmation of the absence of clinical neuropathology by autopsy examination.

Human brain immunohistochemistry
--------------------------------

Middle frontal gyrus tissue blocks were postfixed for 7 days in 4% paraformaldehyde (0.1 M phosphate buffer, pH 7.3) at 4 °C. Tissue was subsequently transferred to 10% sucrose (0.1 [m]{.smallcaps} phosphate buffer, pH 7.3) and stored overnight at 4 °C. Embedding was performed in 12% gelatin/10% sucrose, with fixation in 10% paraformaldehyde/30% sucrose solution for 4 h at room temperature and overnight immersion in 30% sucrose at 4 °C. Serial 40 μm sections were collected along the rostrocaudal axis using a freezing microtome (Leica, Wetzlar, Germany; SM 2000 R) and stored at −20 °C in a solution containing 37.5% ethylene glycol (Avantor, Central Valley, PA, USA, 9300), 37.5% glycerol (VWR Chemicals, Radnor, PA, USA, 24 386.298) and 25% 0.1 [m]{.smallcaps} phosphate buffer. Free-floating sections were washed thoroughly with PBS before being incubated in sodium citrate (10 m[m]{.smallcaps}) at 80 °C for 45 min and rinsed with PBS. Sections were pre-incubated with a blocking PBS buffer containing 1% Triton X-100 and 5% bovine serum albumin for 1 h at room temperature.

Primary antibody labeling was performed in PBS buffer containing 1% Triton X-100 and 1% BSA for 72 h at 4 °C. The following primary antibodies were used: Rabbit anti-RCL1 (1:250, Sigma, St Louis, MO, USA, SAB4500053), Mouse anti-GFAP (1:2000, Sigma, G6171), Mouse anti-MAP2 (1:200, EMD Millipore, Merck Life Sciences, Darmstadt, Germany, MAB3418), Guinea pig anti-MAP2 (1:1000, Synaptic Systems, Goettingen, Germany, 188 004), Mouse anti-SMI31 (1:250, Affinity, Exeter, UK, NA1219), Rat anti-CD44 (1:400, Sigma, SAB4700188). Following primary antibody labeling, sections were washed with PBS and then incubated with corresponding Alexa-conjugated secondary antibodies and cyanine dyes (1:400, Braunschweig Chemicals, Amsterdam, The Netherlands) in PBS buffer containing 1% Triton X-100, 1% BSA for 4 h at room temperature. Nuclear staining was performed using DAPI (1:10 000, Thermo Fisher Scientific, Waltham, MA, USA). Images were acquired using a Zeiss LSM 700 confocal microscope (Carl Zeiss, Oberkochen, Germany).

Mouse brain immunohistochemistry
--------------------------------

All mouse experiments were approved by the local animal welfare committee. Three adult C57BL/6J mice were killed by standard transcardiac perfusion with saline followed by 4% paraformaldehyde. Brains were dissected and postfixed in 4% paraformaldehyde for 2 h at room temperature. Subsequently, 40 μm mouse brain sections were prepared and stained with the same procedures as the human brain sections, with the exceptions that they were: (a) not incubated in sodium citrate, (b) incubated in 0.5% Triton X-100 instead of 1%, (c) blocked with horse serum (Invitrogen) instead of BSA and (d) Mouse anti-GFAP (Sigma, G6171) was used in a 1:20 000 dilution.

Results
=======

Linkage and haplotyping
-----------------------

Results of genome-wide linkage analysis are provided in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. There were 10 genomic regions including 5q14, 9p22-24, 10q21, 11q13, 12q24, 15q21, 19q13, 20p13, 21q22 and 21q24 that showed a log of odds score \>3 ([Table 1](#tbl1){ref-type="table"}). Chromosome 9p22-24 showed over 11 mega-bases (Mb) long haplotype segregating in three generations of the contributing family. The haplotype was shared by all of the affected individuals (*N*=8) in this family ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}) including two homozygous carriers. For linked regions including chromosomes 15q21, 19q13, 20p13 and 21q22, we observed small (\<190 kilo-base (kb)) haplotypes with mixed segregation patterns ([Supplementary Figures 3--6](#sup1){ref-type="supplementary-material"}). For chromosomes 5q14, 10q21 and 11q13 we could not identify clear segregating haplotypes.

Fine mapping using exome sequencing
-----------------------------------

Upon filtering the exome sequence data based on sharing among affected haplotype carriers, we identified a rare c.1114C\>T missense variant (rs115482041) in 6 of the 8 affected haplotype carriers in the 9p22-24 region in the *RCL1* gene ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Within the remaining linkage regions, including 15q21, 19q13, 20p13 and 21q22, we searched for shared variants in heterozygous, homozygous and compound heterozygous forms but identified none that could explain linkage signals in these regions. Rs115482041 was sequenced with a high confidence (read depth=39 × ) and showed a base call accuracy of \>99.99% (Phred scale quality=94). The two homozygous carriers of the haplotype (brothers) were also homozygous for rs115482041-T ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). These two siblings were diagnosed with major depressive disorder (MDD), whereas their sister and her son, who were heterozygous for the rare variant, were both diagnosed with depressive disorder not otherwise specified. The MAF of rs115482041 was 1% in the ERF study compared to 0.16% in 1000 Genomes (<http://www.1000genomes.org/>) and 0.33% in the Exome Sequencing Project (ESP; <http://evs.gs.washington.edu/EVS/>). Rs115482041 is a conserved protein coding variant (genomic evolutionary rate profiling=4.0) and predicted to affect protein function (p.L186F) by three different algorithms (PolyPhen2, 0.68; SIFT, 0.01; MutationTaster, 0.99; combined annotation dependent depletion score, 12.15).

As ERF is a large pedigree spread over 23 generations, we extended this sub-family to more distant relatives to identify other potential carriers to confirm the segregation of rs115482041 ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}). We performed Sanger sequencing of 30 individuals with available HADS-D score from the extended family including two haplotype carriers that did not carry the rs115482041_T variant based on NGS. We identified three more heterozygous carriers of rs115482041_T, two of whom had a high HADS depression score ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}). In total, there were 54/2816 rs115482041_T carriers who were related to each other across five generations ([Figure 1](#fig1){ref-type="fig"}). No Mendelian inconsistencies were observed. A significant association of rs115482041 with the HADS-D was observed (*N*=2393, log of odds=3.24, *P-*value=1x10^−4^). The effect of the rare allele (T) on HADS-D was large (*β*=2.33), indicating a mean increase of 2.33 points for each mutant allele (T) (2.33 points for heterozygote C/T carriers and 4.66 points for homozygous T/T carriers, compared with the reference C/C carriers). The heritability of the HADS-D in the extended sub-pedigree ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}) was estimated to be 94%, and 54% of the variance in depressive symptoms was explained by c.1114C\>T. Across the entire ERF cohort, the heritability of the HADS-D was estimated to be 22%, of which rs115482041 explained 0.64% of the variance in depressive symptoms (2.9% of the genetic variance of HADS-D). We found no evidence to suggest that this association was due to an underlying somatic condition, including cancer, cardiovascular, lung, liver or metabolic phenotypes.

For 17 of the 54 carriers, we were able to obtain medication prescriptions at the time of the HADS assessments. Six were using antidepressant medication and/or benzodiazepines at the time of assessment including selective serotonin reuptake inhibitors (paroxetine, citalopram), non-selective serotonin reuptake inhibitors (imipramine, amitriptyline) and other antidepressants (mirtazapine) coupled with benzodiazepine derivatives (temazepam, oxazepam, alprazolam and bromazepam).

In the replication cohort, we identified 23 rs115482041_T carriers (of whom 17 had completed the CES-D) from a total of 2356 individuals (MAF=0.5%). The rs115482041 variant was sequenced at an average depth of 39 × and showed a base call accuracy of \>99.99% (Phred scale quality=70). A significant association with CES-D was observed (*P*-value=0.03). The effect of rs115482041_T on the CES-D scale was large in RS (*β*=3.60, *δ*~*β*~=1.69), which was comparable to that in ERF (CES-D; *β*=3.47, *δ*~*β*~=1.74).

RCL1 is abundantly expressed in interlaminar astrocytes in human cerebral cortex
--------------------------------------------------------------------------------

RCL1 is an RNA 3′-terminal phosphate cyclase-like protein that is highly conserved across eukaryotic species.^[@bib36]^ The function of the RCL1 protein has predominantly been studied in yeast, where it is has been shown to have nuclease activity that separates 18 S transcripts from the precursor rRNA transcript by co-transcriptional endonucleolytic cleavage. In line with this function, RCL1 has been shown in yeast to have a nucleolar subcellular localization.^[@bib37]^

No previous study has investigated the cell-type specific expression of RCL1 in human brain. Immunohistochemistry of human postmortem cerebral cortex revealed nuclear labeling of RCL1 in most cells ([Supplementary Figure 9a](#sup1){ref-type="supplementary-material"}), including neurons ([Supplementary Figure 9b](#sup1){ref-type="supplementary-material"}). In addition, a distinct pattern of long unbranched tortuous processes often extending from layer 1 to layer 3/4 exhibited abundant RCL1 expression ([Figure 2](#fig2){ref-type="fig"}). These processes showed no co-localization with markers of neuronal processes including MAP2 (dendritic, [Supplementary Figure 10a](#sup1){ref-type="supplementary-material"}) or SMI31 (axonal, [Supplementary Figure 10b](#sup1){ref-type="supplementary-material"}). In contrast, strong co-localization was observed with the astrocyte markers GFAP and CD44 ([Figure 2](#fig2){ref-type="fig"}; [Supplementary Figure 11](#sup1){ref-type="supplementary-material"}) with their cell bodies located in layer 1 of the cortex and a cellular morphology consistent with primate-specific interlaminar astrocytes that extend very long tortuous processes often extending more than a millimeter in length into cortical layers 2--4.^[@bib38]^ The specificity of RCL1 expression in layer 1 interlaminar astrocytes was additionally highlighted by the absence of cytoplasmic RCL1 labeling in GFAP^+^ astrocytes in layer 5/6 of the cerebral cortex ([Supplementary Figure 12](#sup1){ref-type="supplementary-material"}). Moreover, consistent with the recent evolution of interlaminar astrocytes limited to primates, we observed no significant cytoplasmic RCL1 labeling in GFAP^+^ astrocytes of the mouse cerebral cortex ([Supplementary Figure 13](#sup1){ref-type="supplementary-material"}). Immunohistochemistry controls for RCL1 labeling, autofluorescence and nonspecific secondary antibody labeling are presented in [Supplementary Figures 14 and 15](#sup1){ref-type="supplementary-material"}.

Discussion
==========

Using a three-stage design in a family-based setting to discover rare genetic variants influencing depression, we identified a rare genetic variant (rs115482041) on chromosome 9p24 in the *RCL1* gene that segregated with depression across multiple generations in an extended family. The variant was estimated to explain more than half of the variation in depressive symptoms in the extended family, and 2.9% of the heritability in the overall genetically isolated ERF population, which is enriched for rs115482041. The strong association with depressive symptoms was further replicated in the population-based RS cohort.

Rs115482041 is a coding variant (c.1114C\>T, p.L186F) located in a highly conserved RNA Terminal Phosphate Cyclase-Like 1 domain and predicted as damaging. The variant exists only in 8/5008 alleles (MAF=0.16%) in 1000 Genomes and 43/12963 alleles (MAF=0.33%) in the Exome Variant Server. It occurs more frequently in European-Americans (37/8563, MAF=0.43%) compared with the African-Americans (6/4400, MAF=0.14%). In contrast, the ERF pedigree is considerably enriched for rs115482041 carriers (56/5632 alleles, MAF=1%). As a consequence, we had considerably increased power to detect the association with depression. Further, of interest is that both of the homozygous carriers from ERF exhibited high scores on the depressive symptom rating scales and were also diagnosed with MDD requiring a combination of psychotherapy and antidepressant treatment. The association of rs115482041 with depressive symptoms in the population-based Rotterdam Study further confirms the robustness of the finding and its relevance beyond the ERF cohort. We could not find our variant in the top 10 000 findings in the GWAS performed by 23andMe.^[@bib11]^ As the variant rs115482041 is extremely rare in 1000 Genomes, it is very likely that the variant may not have been analyzed because of poor imputation quality^[@bib39]^ (in ERF the imputation quality of rs115482041 based on the same release of 1000 Genomes is 0.09).

RCL1 is ubiquitously expressed in eukaryotes with a demonstrated function in ribosome biogenesis. Our findings now suggest that RCL1 might have additional functions in the human brain. In contrast to the mouse brain, immunohistochemistry of RCL1 expression in human brain identified abundant labeling of interlaminar astrocytes in layer 1 of the cerebral cortex, with their characteristic tortuous processes extending long distances of hundreds of microns into deeper cortical layers. Notably, recent studies in rodent models^[@bib40],\ [@bib41]^ and humans^[@bib42],\ [@bib43],\ [@bib44]^ have proposed novel pathophysiological functions of astrocytes in MDD. However, the neurobiological function of interlaminar astrocytes remains largely unknown. Interestingly, their extensive projections have been hypothesized to form a network for long-range coordination of intra-cortical communication.^[@bib38],\ [@bib45],\ [@bib46],\ [@bib47]^ On the other hand, we also found evidence for the presence of RCL1 in neurons for which we cannot yet distinguish the relative contribution of neuronal and/or astrocyte dysfunction that might explain the genetic association with *RCL1* c.1114C\>T (p.L186F). Future studies should be performed to elucidate the function of interlaminar astrocytes and their potential influence on the pathophysiology of depression.

In this study we used a unique multistep approach to identify rare genetic variants that confer large effects on depression. Our study design had several advantages. First, the discovery cohort ERF was enriched for the rs115482041_T variant, which led to an increase in statistical power to detect genotype/phenotype association. Secondly, using haplotype analysis we were able to identify the most relevant individuals for each locus that facilitated the identification of segregating candidate variants using the filtering/sharing approach. Finally, by combining linkage, haplotype sharing and filtering, we contained the problem of multiple testing. Importantly however, despite these distinct advantages we were able to identify a genetic variant for only one of the several linked genomic regions, for which, there may be several reasons including structural variants, and intronic or intergenic single-nucleotide variants that were not evaluated in the current study. Notably, many of the other haplotype regions were relatively small (a few kb) and therefore of questionable relevance, compared with that of the 9p22-24 locus which was nearly 11 Mb. As ERF is a young genetic isolate with high rate of consanguinity, 500 kb--1.5 Mb homozygous blocks may just be shared by chance.^[@bib48]^ Notably, however, we previously found that some of these additional loci are significantly linked with personality traits, including conscientiousness (20p13), extraversion (12q24), openness (12q24 and 19q13), neuroticism (19q13 and 21q22-24) and agreeableness (21q22).^[@bib49]^

In summary, our findings identify *RCL1* as an important candidate gene for depression in a region that shows genome-wide significant linkage with depressive symptoms in the general population. We show that the RCL1 protein is present in human brain, including neurons and astrocytes. Further research is needed to elucidate the mechanism of *RCL1* in the pathogenesis of depression.
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![All carriers of c.1114C\>T in the Erasmus Rucphen Family (ERF) study. Males are depicted with squares and females with circles. The text below each individual shows his/her age followed by the score on HADS-D scale, genotype and psychiatric diagnosis (mdd refers to major depressive disorder/lifetime depression and mild refers to depression not otherwise specified), if any. Individuals connected with dotted lines are duplicates. Dots indicate missing values. HADS, Hospital Anxiety Depression Scale.](mp201749f1){#fig1}

![Immunohistochemical labeling of RCL1 in human cerebral cortex. (**a**) Overview of RCL1 labeling showing co-localization with long (\>350 μm) tortuous interlaminar GFAP-positive extensions (the dashed line marks the approximate border between cortical layers I and II, scale bar=50 μm). (**b**) Higher magnification of marked region in **a** (scale bar=12 μm).](mp201749f2){#fig2}

###### All regions with a (heterogeneity) log of odds \>3

  *chr*     *Start snp*   *End snp*   *From-bp (hg19)*   *To-bp (hg19)*   *Dominant (HLOD)*   *Recessive (HLOD)*   *NPL (LOD)*
  --------- ------------- ----------- ------------------ ---------------- ------------------- -------------------- -------------
  5q14      rs4704223     rs173686    74773420           82811500         2.18                3.20                 2.33
  9p22-24   rs7851353     rs1888952   4411383            16258118         3.71                2.52                 3.44
  10q21     rs1338799     rs377859    57629679           64516065         2.30                3.45                 2.90
  11q13     rs1530354     rs7122786   60200446           69029210         2.55                3.15                 2.78
  12q24.3   rs1545610     rs7960480   132175484          133778166        4.33                5.78                 4.67
  15q21     rs347117      rs610877    59000957           59103328         3.56                4.91                 5.17
  19q13.4   rs260462      rs3499      58774071           59093484         3.64                5.31                 5.16
  20p13     rs1434789     rs434609    137900             236992           3.94                5.02                 4.64
  21q22     rs1012959     rs2836301   38061622           39677589         5.03                6.84                 7.32
  21q24     rs2968        rs2839377   47608580           48077812         4.80                4.91                 4.83

Abbreviations: HLOD, heterogeneity log of odds; LOD, log of odds.

[^1]: These authors contributed equally to this work.
